Clinical Trial Update: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD) [Phase 2]

View source ↗

Summary

Phase II clinical trial ABSK021 (Pimicotinib) for chronic graft-versus-host disease is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• ABSK021 (Pimicotinib) (Pimicotinib)

Snippet

Sponsor: Abbisko Therapeutics Co, Ltd | Conditions: cGvHD | Phase 2 | Status: ENROLLING_BY_INVITATION